NIPT: Expert insights on the advantages of the verfi® Prenatal Test: Dr. Platt | Illumina Video

29 April 2015

Dr. Larry Platt, Director of the Center for Fetal Medicine and Women’s Ultrasound in Los Angeles CA, discusses the clinical utility of NIPT / the verifi Test [http://www.illumina.com/clinical/reproductive-genetic-health/healthcare-professionals/non-invasive-prenatal-testing.html] and highlights reliability and sensitivity data from the CARE Study published in the NEJM http://www.nejm.org/doi/full/10.1056/NEJMoa1311037

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.